KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biomarin Pharmaceutical (BMRN) Cost of Revenue (2017 - 2025)

Historic Cost of Revenue for Biomarin Pharmaceutical (BMRN) over the last 16 years, with Q3 2025 value amounting to $140.1 million.

  • Biomarin Pharmaceutical's Cost of Revenue fell 2566.74% to $140.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $577.9 million, marking a year-over-year decrease of 71.37%. This contributed to the annual value of $580.2 million for FY2024, which is 905.4% up from last year.
  • Per Biomarin Pharmaceutical's latest filing, its Cost of Revenue stood at $140.1 million for Q3 2025, which was down 2566.74% from $150.1 million recorded in Q2 2025.
  • Over the past 5 years, Biomarin Pharmaceutical's Cost of Revenue peaked at $188.5 million during Q3 2024, and registered a low of $103.5 million during Q3 2021.
  • Over the past 5 years, Biomarin Pharmaceutical's median Cost of Revenue value was $130.5 million (recorded in 2024), while the average stood at $133.0 million.
  • Its Cost of Revenue has fluctuated over the past 5 years, first plummeted by 4515.85% in 2021, then skyrocketed by 4718.49% in 2024.
  • Biomarin Pharmaceutical's Cost of Revenue (Quarter) stood at $119.8 million in 2021, then increased by 22.46% to $146.6 million in 2022, then dropped by 5.94% to $137.9 million in 2023, then decreased by 1.3% to $136.1 million in 2024, then increased by 2.9% to $140.1 million in 2025.
  • Its Cost of Revenue stands at $140.1 million for Q3 2025, versus $150.1 million for Q2 2025 and $151.6 million for Q1 2025.